-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As the world's largest cause of death, cardiovascular disease seriously affects people's health
.
Cardiovascular diseases include coronary heart disease, arrhythmia, heart failure, etc.
, from detection to diagnosis to treatment, involving a wide range of medical equipment products
.
With the increase in the number of patients, the demand for cardiovascular medical devices is rising, and the market development space is broad
.
.
Cardiovascular diseases include coronary heart disease, arrhythmia, heart failure, etc.
, from detection to diagnosis to treatment, involving a wide range of medical equipment products
.
With the increase in the number of patients, the demand for cardiovascular medical devices is rising, and the market development space is broad
.
Rising demand drives market expansion
The "Global Health Statistics Report 2019" released by the World Health Organization shows that from 2000 to 2019, heart disease was the world's leading cause of death
.
In the meantime, the number of deaths from heart disease increased by more than 2 million
.
.
In the meantime, the number of deaths from heart disease increased by more than 2 million
.
In July this year, the "China Cardiovascular Health and Disease Report 2020" issued by the National Cardiovascular Disease Center of China pointed out that in recent years, the incidence of cardiovascular disease in China has continued to increase.
The report estimates that the number of cardiovascular disease patients is 330 million, and The morbidity rate is in a stage of continuous increase, and the economic burden of cardiovascular disease on residents and society is increasing day by day
.
The report data also shows that cardiovascular disease is the leading cause of death among urban and rural residents in China, and 2 out of every 5 deaths are due to cardiovascular disease
.
The report estimates that the number of cardiovascular disease patients is 330 million, and The morbidity rate is in a stage of continuous increase, and the economic burden of cardiovascular disease on residents and society is increasing day by day
.
The report data also shows that cardiovascular disease is the leading cause of death among urban and rural residents in China, and 2 out of every 5 deaths are due to cardiovascular disease
.
High morbidity and high mortality rates have driven the demand for cardiovascular medical devices to rise, driving the continued expansion of the market
.
At present, from a global perspective, among the various segments of medical devices, the cardiovascular market ranks second, second only to the in vitro diagnostic field; the market size is expected to grow from US$52.
6 billion in 2017 to US$79.
6 billion in 2024 , The compound annual growth rate is about 6.
4%; at the same time, the market share will increase from 11.
6% to 12.
2%
.
.
At present, from a global perspective, among the various segments of medical devices, the cardiovascular market ranks second, second only to the in vitro diagnostic field; the market size is expected to grow from US$52.
6 billion in 2017 to US$79.
6 billion in 2024 , The compound annual growth rate is about 6.
4%; at the same time, the market share will increase from 11.
6% to 12.
2%
.
Cardiovascular field has become the main position of innovative R&D
Cardiovascular medical devices are one of the main fronts of innovative research and development in China's medical device industry, which are mainly divided into diagnostic products and therapeutic products
.
Among them, diagnostic products include electrocardiographs, intravascular imaging systems, coronary blood flow evaluation systems, and heart label products in the field of in vitro diagnostics; therapeutic products include stents, balloons, valves, cardiac pacemakers, and occluders , radiofrequency ablation based products
.
.
Among them, diagnostic products include electrocardiographs, intravascular imaging systems, coronary blood flow evaluation systems, and heart label products in the field of in vitro diagnostics; therapeutic products include stents, balloons, valves, cardiac pacemakers, and occluders , radiofrequency ablation based products
.
Since 2004, many domestic drug-eluting coronary stents have been approved for marketing, which are comparable to imported stents in terms of raw material selection, bare stent processing technology, and drug coating technology
.
At present, the domestic heart stent market accounts for more than 80%, and it is one of the segments with the fastest import substitution process among high-value medical consumables
.
.
At present, the domestic heart stent market accounts for more than 80%, and it is one of the segments with the fastest import substitution process among high-value medical consumables
.
According to statistics published by the State Food and Drug Administration, from 2018 to July this year, a total of 33 cardiovascular stent products in China were approved, including 15 drug stents and 3 degradable stents
.
As of May 31, a total of 39 cardiovascular stent products have entered the special review channel for innovative medical devices, involving coronary stents, aortic stents, peripheral arterial stents and venous stents, among which 7 products have been approved through this channel Listed
.
.
As of May 31, a total of 39 cardiovascular stent products have entered the special review channel for innovative medical devices, involving coronary stents, aortic stents, peripheral arterial stents and venous stents, among which 7 products have been approved through this channel Listed
.
For the damaged heart valve structure that cannot be reversed by medical treatment, it is usually treated by surgery
.
At present, the development rate of surgical operations for heart valve diseases in China is relatively low.
In the future, as the penetration rate of surgical treatment increases, the heart valve medical device industry will usher in a broad space for development
.
.
At present, the development rate of surgical operations for heart valve diseases in China is relatively low.
In the future, as the penetration rate of surgical treatment increases, the heart valve medical device industry will usher in a broad space for development
.
According to statistics published by the State Food and Drug Administration, from 2018 to July this year, a total of 6 heart valve products in China were approved, including 2 mechanical valves, 3 biological valves and 1 interventional valve; in addition, there are 2 The heart valvuloplasty ring was approved
.
As of May 31, 14 heart valve products have been included in the special review channel for innovative medical devices, of which 7 products (1 heart valvuloplasty ring, 6 interventional valves) have been approved for marketing through this channel
.
At present, more than 80% of patients with heart valve disease in China choose to use mechanical valves
.
In the future, with the advancement of biological valve and interventional valve technology, the reduction of prices and the promotion of clinical applications, the market penetration rate will gradually increase
.
.
As of May 31, 14 heart valve products have been included in the special review channel for innovative medical devices, of which 7 products (1 heart valvuloplasty ring, 6 interventional valves) have been approved for marketing through this channel
.
At present, more than 80% of patients with heart valve disease in China choose to use mechanical valves
.
In the future, with the advancement of biological valve and interventional valve technology, the reduction of prices and the promotion of clinical applications, the market penetration rate will gradually increase
.
At present, in addition to cardiovascular stents and heart valve products, a variety of radiofrequency ablation, cardiac pacing, intravascular imaging, coronary blood flow evaluation, balloon, and occluder products have also been included in the innovation Special inspection channels for medical devices were approved for listing (see picture)
.
.
Centralized procurement accelerates industry reshuffle
In October 2020, the national organization of the centralized procurement of coronary stents issued documents, officially launching the national centralized procurement of high-value medical consumables, and coronary stents became the first batch of centralized procurement targets
.
On November 5 of that year, the national organization of centralized procurement of coronary stents produced a planned selection in Tianjin.
The unit price dropped from about 13,000 yuan to about 700 yuan, and the average price reduction reached 93%
.
.
On November 5 of that year, the national organization of centralized procurement of coronary stents produced a planned selection in Tianjin.
The unit price dropped from about 13,000 yuan to about 700 yuan, and the average price reduction reached 93%
.
At present, various provinces across the country have successively carried out the centralized procurement of high-value medical consumables through independent or joining provincial alliances.
Among them, coronary stents, balloons, and pacemakers have become high-frequency varieties
.
Among them, coronary stents, balloons, and pacemakers have become high-frequency varieties
.
After the start of centralized procurement, companies actively cut prices in exchange for market share.
Companies that have not won the bid may face the risk of being marginalized.
The entire industry will be reshuffled and concentration will increase
.
At the same time, the method of relying on a single large variety to gain market share is no longer reliable
.
With the help of centralized procurement, enterprises can accelerate the pace of innovation and transformation, and actively enrich their product pipelines and levels to enhance their competitiveness
.
(Author's unit: Firestone Creation)
Companies that have not won the bid may face the risk of being marginalized.
The entire industry will be reshuffled and concentration will increase
.
At the same time, the method of relying on a single large variety to gain market share is no longer reliable
.
With the help of centralized procurement, enterprises can accelerate the pace of innovation and transformation, and actively enrich their product pipelines and levels to enhance their competitiveness
.
(Author's unit: Firestone Creation)
As the world's largest cause of death, cardiovascular disease seriously affects people's health
.
Cardiovascular diseases include coronary heart disease, arrhythmia, heart failure, etc.
, from detection to diagnosis to treatment, involving a wide range of medical equipment products
.
With the increase in the number of patients, the demand for cardiovascular medical devices is rising, and the market development space is broad
.
.
Cardiovascular diseases include coronary heart disease, arrhythmia, heart failure, etc.
, from detection to diagnosis to treatment, involving a wide range of medical equipment products
.
With the increase in the number of patients, the demand for cardiovascular medical devices is rising, and the market development space is broad
.
Rising demand drives market expansion
The "Global Health Statistics Report 2019" released by the World Health Organization shows that from 2000 to 2019, heart disease was the world's leading cause of death
.
In the meantime, the number of deaths from heart disease increased by more than 2 million
.
.
In the meantime, the number of deaths from heart disease increased by more than 2 million
.
In July this year, the "China Cardiovascular Health and Disease Report 2020" issued by the National Cardiovascular Disease Center of China pointed out that in recent years, the incidence of cardiovascular disease in China has continued to increase.
The report estimates that the number of cardiovascular disease patients is 330 million, and The morbidity rate is in a stage of continuous increase, and the economic burden of cardiovascular disease on residents and society is increasing day by day
.
The report data also shows that cardiovascular disease is the leading cause of death among urban and rural residents in China, and 2 out of every 5 deaths are due to cardiovascular disease
.
The report estimates that the number of cardiovascular disease patients is 330 million, and The morbidity rate is in a stage of continuous increase, and the economic burden of cardiovascular disease on residents and society is increasing day by day
.
The report data also shows that cardiovascular disease is the leading cause of death among urban and rural residents in China, and 2 out of every 5 deaths are due to cardiovascular disease
.
High morbidity and high mortality rates have driven the demand for cardiovascular medical devices to rise, driving the continued expansion of the market
.
At present, from a global perspective, among the various segments of medical devices, the cardiovascular market ranks second, second only to the in vitro diagnostic field; the market size is expected to grow from US$52.
6 billion in 2017 to US$79.
6 billion in 2024 , The compound annual growth rate is about 6.
4%; at the same time, the market share will increase from 11.
6% to 12.
2%
.
.
At present, from a global perspective, among the various segments of medical devices, the cardiovascular market ranks second, second only to the in vitro diagnostic field; the market size is expected to grow from US$52.
6 billion in 2017 to US$79.
6 billion in 2024 , The compound annual growth rate is about 6.
4%; at the same time, the market share will increase from 11.
6% to 12.
2%
.
Cardiovascular field has become the main position of innovative R&D
Cardiovascular medical devices are one of the main fronts of innovative research and development in China's medical device industry, which are mainly divided into diagnostic products and therapeutic products
.
Among them, diagnostic products include electrocardiographs, intravascular imaging systems, coronary blood flow evaluation systems, and heart label products in the field of in vitro diagnostics; therapeutic products include stents, balloons, valves, cardiac pacemakers, and occluders , radiofrequency ablation based products
.
.
Among them, diagnostic products include electrocardiographs, intravascular imaging systems, coronary blood flow evaluation systems, and heart label products in the field of in vitro diagnostics; therapeutic products include stents, balloons, valves, cardiac pacemakers, and occluders , radiofrequency ablation based products
.
Since 2004, many domestic drug-eluting coronary stents have been approved for marketing, which are comparable to imported stents in terms of raw material selection, bare stent processing technology, and drug coating technology
.
At present, the domestic heart stent market accounts for more than 80%, and it is one of the segments with the fastest import substitution process among high-value medical consumables
.
.
At present, the domestic heart stent market accounts for more than 80%, and it is one of the segments with the fastest import substitution process among high-value medical consumables
.
According to statistics published by the State Food and Drug Administration, from 2018 to July this year, a total of 33 cardiovascular stent products in China were approved, including 15 drug stents and 3 degradable stents
.
As of May 31, a total of 39 cardiovascular stent products have entered the special review channel for innovative medical devices, involving coronary stents, aortic stents, peripheral arterial stents and venous stents, among which 7 products have been approved through this channel Listed
.
.
As of May 31, a total of 39 cardiovascular stent products have entered the special review channel for innovative medical devices, involving coronary stents, aortic stents, peripheral arterial stents and venous stents, among which 7 products have been approved through this channel Listed
.
For the damaged heart valve structure that cannot be reversed by medical treatment, it is usually treated by surgery
.
At present, the development rate of surgical operations for heart valve diseases in China is relatively low.
In the future, as the penetration rate of surgical treatment increases, the heart valve medical device industry will usher in a broad space for development
.
.
At present, the development rate of surgical operations for heart valve diseases in China is relatively low.
In the future, as the penetration rate of surgical treatment increases, the heart valve medical device industry will usher in a broad space for development
.
According to statistics published by the State Food and Drug Administration, from 2018 to July this year, a total of 6 heart valve products in China were approved, including 2 mechanical valves, 3 biological valves and 1 interventional valve; in addition, there are 2 The heart valvuloplasty ring was approved
.
As of May 31, 14 heart valve products have been included in the special review channel for innovative medical devices, of which 7 products (1 heart valvuloplasty ring, 6 interventional valves) have been approved for marketing through this channel
.
At present, more than 80% of patients with heart valve disease in China choose to use mechanical valves
.
In the future, with the advancement of biological valve and interventional valve technology, the reduction of prices and the promotion of clinical applications, the market penetration rate will gradually increase
.
.
As of May 31, 14 heart valve products have been included in the special review channel for innovative medical devices, of which 7 products (1 heart valvuloplasty ring, 6 interventional valves) have been approved for marketing through this channel
.
At present, more than 80% of patients with heart valve disease in China choose to use mechanical valves
.
In the future, with the advancement of biological valve and interventional valve technology, the reduction of prices and the promotion of clinical applications, the market penetration rate will gradually increase
.
At present, in addition to cardiovascular stents and heart valve products, a variety of radiofrequency ablation, cardiac pacing, intravascular imaging, coronary blood flow evaluation, balloon, and occluder products have also been included in the innovation Special inspection channels for medical devices were approved for listing (see picture)
.
.
Centralized procurement accelerates industry reshuffle
In October 2020, the national organization of the centralized procurement of coronary stents issued documents, officially launching the national centralized procurement of high-value medical consumables, and coronary stents became the first batch of centralized procurement targets
.
On November 5 of that year, the national organization of centralized procurement of coronary stents produced a planned selection in Tianjin.
The unit price dropped from about 13,000 yuan to about 700 yuan, and the average price reduction reached 93%
.
.
On November 5 of that year, the national organization of centralized procurement of coronary stents produced a planned selection in Tianjin.
The unit price dropped from about 13,000 yuan to about 700 yuan, and the average price reduction reached 93%
.
At present, various provinces across the country have successively carried out the centralized procurement of high-value medical consumables through independent or joining provincial alliances.
Among them, coronary stents, balloons, and pacemakers have become high-frequency varieties
.
Among them, coronary stents, balloons, and pacemakers have become high-frequency varieties
.
After the start of centralized procurement, companies actively cut prices in exchange for market share.
Companies that have not won the bid may face the risk of being marginalized.
The entire industry will be reshuffled and concentration will increase
.
At the same time, the method of relying on a single large variety to gain market share is no longer reliable
.
With the help of centralized procurement, enterprises can accelerate the pace of innovation and transformation, and actively enrich their product pipelines and levels to enhance their competitiveness
.
(Author's unit: Firestone Creation)
Companies that have not won the bid may face the risk of being marginalized.
The entire industry will be reshuffled and concentration will increase
.
At the same time, the method of relying on a single large variety to gain market share is no longer reliable
.
With the help of centralized procurement, enterprises can accelerate the pace of innovation and transformation, and actively enrich their product pipelines and levels to enhance their competitiveness
.
(Author's unit: Firestone Creation)
As the world's largest cause of death, cardiovascular disease seriously affects people's health
.
Cardiovascular diseases include coronary heart disease, arrhythmia, heart failure, etc.
, from detection to diagnosis to treatment, involving a wide range of medical equipment products
.
With the increase in the number of patients, the demand for cardiovascular medical devices is rising, and the market development space is broad
.
.
Cardiovascular diseases include coronary heart disease, arrhythmia, heart failure, etc.
, from detection to diagnosis to treatment, involving a wide range of medical equipment products
.
With the increase in the number of patients, the demand for cardiovascular medical devices is rising, and the market development space is broad
.
Rising demand drives market expansion
Rising demand drives market expansion The "Global Health Statistics Report 2019" released by the World Health Organization shows that from 2000 to 2019, heart disease was the world's leading cause of death
.
In the meantime, the number of deaths from heart disease increased by more than 2 million
.
.
In the meantime, the number of deaths from heart disease increased by more than 2 million
.
In July this year, the "China Cardiovascular Health and Disease Report 2020" issued by the National Cardiovascular Disease Center of China pointed out that in recent years, the incidence of cardiovascular disease in China has continued to increase.
The report estimates that the number of cardiovascular disease patients is 330 million, and The morbidity rate is in a stage of continuous increase, and the economic burden of cardiovascular disease on residents and society is increasing day by day
.
The report data also shows that cardiovascular disease is the leading cause of death among urban and rural residents in China, and 2 out of every 5 deaths are due to cardiovascular disease
.
Health Health health diseases disease diseaseThe report estimates that the number of cardiovascular disease patients is 330 million, and The morbidity rate is in a stage of continuous increase, and the economic burden of cardiovascular disease on residents and society is increasing day by day
.
The report data also shows that cardiovascular disease is the leading cause of death among urban and rural residents in China, and 2 out of every 5 deaths are due to cardiovascular disease
.
High morbidity and high mortality rates have driven the demand for cardiovascular medical devices to rise, driving the continued expansion of the market
.
At present, from a global perspective, among the various segments of medical devices, the cardiovascular market ranks second, second only to the in vitro diagnostic field; the market size is expected to grow from US$52.
6 billion in 2017 to US$79.
6 billion in 2024 , The compound annual growth rate is about 6.
4%; at the same time, the market share will increase from 11.
6% to 12.
2%
.
Medical equipment medical equipment medical equipment.
At present, from a global perspective, among the various segments of medical devices, the cardiovascular market ranks second, second only to the in vitro diagnostic field; the market size is expected to grow from US$52.
6 billion in 2017 to US$79.
6 billion in 2024 , The compound annual growth rate is about 6.
4%; at the same time, the market share will increase from 11.
6% to 12.
2%
.
Cardiovascular field has become the main position of innovative R&D
Cardiovascular field has become the main position of innovative R&D Cardiovascular medical devices are one of the main fronts of innovative research and development in China's medical device industry, which are mainly divided into diagnostic products and therapeutic products
.
Among them, diagnostic products include electrocardiographs, intravascular imaging systems, coronary blood flow evaluation systems, and heart label products in the field of in vitro diagnostics; therapeutic products include stents, balloons, valves, cardiac pacemakers, and occluders , radiofrequency ablation based products
.
.
Among them, diagnostic products include electrocardiographs, intravascular imaging systems, coronary blood flow evaluation systems, and heart label products in the field of in vitro diagnostics; therapeutic products include stents, balloons, valves, cardiac pacemakers, and occluders , radiofrequency ablation based products
.
Since 2004, many domestic drug-eluting coronary stents have been approved for marketing, which are comparable to imported stents in terms of raw material selection, bare stent processing technology, and drug coating technology
.
At present, the domestic heart stent market accounts for more than 80%, and it is one of the segments with the fastest import substitution process among high-value medical consumables
.
.
At present, the domestic heart stent market accounts for more than 80%, and it is one of the segments with the fastest import substitution process among high-value medical consumables
.
According to statistics published by the State Food and Drug Administration, from 2018 to July this year, a total of 33 cardiovascular stent products in China were approved, including 15 drug stents and 3 degradable stents
.
As of May 31, a total of 39 cardiovascular stent products have entered the special review channel for innovative medical devices, involving coronary stents, aortic stents, peripheral arterial stents and venous stents, among which 7 products have been approved through this channel Listed
.
.
As of May 31, a total of 39 cardiovascular stent products have entered the special review channel for innovative medical devices, involving coronary stents, aortic stents, peripheral arterial stents and venous stents, among which 7 products have been approved through this channel Listed
.
For the damaged heart valve structure that cannot be reversed by medical treatment, it is usually treated by surgery
.
At present, the development rate of surgical operations for heart valve diseases in China is relatively low.
In the future, as the penetration rate of surgical treatment increases, the heart valve medical device industry will usher in a broad space for development
.
.
At present, the development rate of surgical operations for heart valve diseases in China is relatively low.
In the future, as the penetration rate of surgical treatment increases, the heart valve medical device industry will usher in a broad space for development
.
According to statistics published by the State Food and Drug Administration, from 2018 to July this year, a total of 6 heart valve products in China were approved, including 2 mechanical valves, 3 biological valves and 1 interventional valve; in addition, there are 2 The heart valvuloplasty ring was approved
.
As of May 31, 14 heart valve products have been included in the special review channel for innovative medical devices, of which 7 products (1 heart valvuloplasty ring, 6 interventional valves) have been approved for marketing through this channel
.
At present, more than 80% of patients with heart valve disease in China choose to use mechanical valves
.
In the future, with the advancement of biological valve and interventional valve technology, the reduction of prices and the promotion of clinical applications, the market penetration rate will gradually increase
.
.
As of May 31, 14 heart valve products have been included in the special review channel for innovative medical devices, of which 7 products (1 heart valvuloplasty ring, 6 interventional valves) have been approved for marketing through this channel
.
At present, more than 80% of patients with heart valve disease in China choose to use mechanical valves
.
In the future, with the advancement of biological valve and interventional valve technology, the reduction of prices and the promotion of clinical applications, the market penetration rate will gradually increase
.
At present, in addition to cardiovascular stents and heart valve products, a variety of radiofrequency ablation, cardiac pacing, intravascular imaging, coronary blood flow evaluation, balloon, and occluder products have also been included in the innovation Special inspection channels for medical devices were approved for listing (see picture)
.
.
Centralized procurement accelerates industry reshuffle
Centralized procurement accelerates industry reshuffle In October 2020, the national organization of the centralized procurement of coronary stents issued documents, officially launching the national centralized procurement of high-value medical consumables, and coronary stents became the first batch of centralized procurement targets
.
On November 5 of that year, the national organization of centralized procurement of coronary stents produced a planned selection in Tianjin.
The unit price dropped from about 13,000 yuan to about 700 yuan, and the average price reduction reached 93%
.
Procurement Procurement Procurement.
On November 5 of that year, the national organization of centralized procurement of coronary stents produced a planned selection in Tianjin.
The unit price dropped from about 13,000 yuan to about 700 yuan, and the average price reduction reached 93%
.
At present, various provinces across the country have successively carried out the centralized procurement of high-value medical consumables through independent or joining provincial alliances.
Among them, coronary stents, balloons, and pacemakers have become high-frequency varieties
.
Among them, coronary stents, balloons, and pacemakers have become high-frequency varieties
.
After the start of centralized procurement, companies actively cut prices in exchange for market share.
Companies that have not won the bid may face the risk of being marginalized.
The entire industry will be reshuffled and concentration will increase
.
At the same time, the method of relying on a single large variety to gain market share is no longer reliable
.
With the help of centralized procurement, enterprises can accelerate the pace of innovation and transformation, and actively enrich their product pipelines and levels to enhance their competitiveness
.
(Author's unit: Firestone Creation)
Enterprise business enterprise Companies that have not won the bid may face the risk of being marginalized.
The entire industry will be reshuffled and concentration will increase
.
At the same time, the method of relying on a single large variety to gain market share is no longer reliable
.
With the help of centralized procurement, enterprises can accelerate the pace of innovation and transformation, and actively enrich their product pipelines and levels to enhance their competitiveness
.
(Author's unit: Firestone Creation)
